Erschienen in:
03.08.2017 | Editorial
Vonoprazan-Based Helicobacter pylori Eradication Therapy: Time to Get Kompetitive?
verfasst von:
Eun Hye Kim, Chan Hyuk Park
Erschienen in:
Digestive Diseases and Sciences
|
Ausgabe 11/2017
Einloggen, um Zugang zu erhalten
Excerpt
Approximately one-half of the world’s population is reported to be infected with
Helicobacter pylori [
1], a cause of numerous gastrointestinal diseases including gastric or duodenal ulcers, gastric mucosa-associated lymphoid tissue (MALT) lymphoma, and gastric cancer [
2,
3]. Eradication of
H. pylori is the first option for the treatment of low-grade gastric MALT lymphoma. Furthermore,
H. pylori eradication reduces the recurrence of peptic ulcer [
4]. A recent Cochrane review reported that the risk of gastric cancer may be reduced through
H. pylori eradication, particularly in Asia [
5]. …